ASLN vs. PPBT, ALLR, SONN, SNPX, BNOX, ONCO, PRTG, MAAQ, PHIO, and PALI
Should you be buying ASLAN Pharmaceuticals stock or one of its competitors? The main competitors of ASLAN Pharmaceuticals include Purple Biotech (PPBT), Allarity Therapeutics (ALLR), Sonnet BioTherapeutics (SONN), Synaptogenix (SNPX), Bionomics (BNOX), Onconetix (ONCO), Portage Biotech (PRTG), Mana Capital Acquisition (MAAQ), Phio Pharmaceuticals (PHIO), and Palisade Bio (PALI). These companies are all part of the "pharmaceutical products" industry.
ASLAN Pharmaceuticals vs.
ASLAN Pharmaceuticals (NASDAQ:ASLN) and Purple Biotech (NASDAQ:PPBT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, community ranking, institutional ownership, analyst recommendations, risk, profitability and earnings.
Purple Biotech has lower revenue, but higher earnings than ASLAN Pharmaceuticals. Purple Biotech is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, ASLAN Pharmaceuticals' average media sentiment score of 0.00 equaled Purple Biotech'saverage media sentiment score.
ASLAN Pharmaceuticals received 183 more outperform votes than Purple Biotech when rated by MarketBeat users. However, 94.44% of users gave Purple Biotech an outperform vote while only 63.49% of users gave ASLAN Pharmaceuticals an outperform vote.
58.8% of ASLAN Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.6% of Purple Biotech shares are owned by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are owned by insiders. Comparatively, 3.0% of Purple Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Purple Biotech's return on equity of -55.86% beat ASLAN Pharmaceuticals' return on equity.
ASLAN Pharmaceuticals currently has a consensus price target of $76.00, suggesting a potential upside of 12,566.67%. Purple Biotech has a consensus price target of $33.00, suggesting a potential upside of 832.20%. Given ASLAN Pharmaceuticals' higher possible upside, analysts clearly believe ASLAN Pharmaceuticals is more favorable than Purple Biotech.
ASLAN Pharmaceuticals has a beta of 1.4, meaning that its stock price is 40% more volatile than the S&P 500. Comparatively, Purple Biotech has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500.
Summary
ASLAN Pharmaceuticals beats Purple Biotech on 8 of the 13 factors compared between the two stocks.
Get ASLAN Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ASLN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ASLAN Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:ASLN) was last updated on 1/22/2025 by MarketBeat.com Staff
Free ASLN Stock Alerts